Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M193Revenue $M50.4Net Margin (%)13.3Altman Z-Score10.8
Enterprise Value $M148EPS $0.3Operating Margin %12.3Piotroski F-Score5
P/E(ttm)28.2Beneish M-Score-2.7Pre-tax Margin (%)13.2Higher ROA y-yN
Price/Book1.410-y EBITDA Growth Rate %--Quick Ratio5.7Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %--Current Ratio7.7Lower Leverage y-yY
Price/Free Cash Flow23.6y-y EBITDA Growth Rate %-10.9ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)5.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M22.7ROIC % (ttm)6.2Gross Margin Increase y-yN

Gurus Latest Trades with ENZY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ENZYJulian Robertson 2015-12-31 Add0.45%$8.47 - $10.1
$ 8.48-11%Add 44.48%1,162,845
ENZYJulian Robertson 2015-09-30 Buy 0.97%$7.38 - $10.56
$ 8.48-5%New holding804,854
ENZYJohn Paulson 2014-03-31 Sold Out -0.23%$21.52 - $29.5
$ 8.48-68%Sold Out0
ENZYJohn Paulson 2013-12-31 Buy 0.23%$16.555 - $33.44
$ 8.48-64%New holding1,733,030
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ENZY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

ENZY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about ENZY :

Quarterly/Annual Reports about ENZY:

    News about ENZY:

    Articles On GuruFocus.com
    Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015 
    What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

    More From Other Websites
    New Survey Shows Nearly 3 Out of 4 Children Treated for ADHD Have Taken a “Drug Holiday” May 04 2016
    2016-05-03 Enzymatica insiders plan to subscribe for SEK 16 million in new issue May 03 2016
    New Retrospective Study Shows PS-Omega-3 Medical Food Effective in Managing ADHD Apr 26 2016
    2016-04-26 Notice of annual general meeting in Enzymatica AB (publ) Apr 26 2016
    2016-04-20 Enzymatica publishes prospectus Apr 20 2016
    2016-04-20 Enzymatica - publication of the annual report 2015 Apr 20 2016
    2016-04-18 Interim Report for Enzymatica AB (publ) January-March 2016 Apr 18 2016
    2016-04-01 Enzymatica completes acquisition of Zymetech and includes new board members and... Apr 01 2016
    Enzymotec Ltd. Granted Patents in U.S. for Compositions and Processes Related to Infant Nutrition... Mar 29 2016
    Enzymotec Ltd. Granted Patents in U.S. for Compositions and Processes Related to Infant Nutrition... Mar 29 2016
    2016-03-24 Acting CFO of Enzymatica appointed Mar 24 2016
    InCog™, Enzymotec's Innovative Lipid Composition for Cognitive Functioning, Enhances Brain... Mar 16 2016
    ENZYMOTEC LTD. Financials Mar 09 2016
    Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2015 Mar 08 2016
    Enzymotec (ENZY): Moving Average Crossover Alert Mar 08 2016
    Edited Transcript of ENZY earnings conference call or presentation 17-Feb-16 1:30pm GMT Feb 22 2016
    Enzymotec Ltd. Earnings Analysis: 2015 By the Numbers Feb 22 2016
    CORRECTING and REPLACING -- Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results Feb 17 2016
    Enzymotec Ltd Earnings Call scheduled for 8:30 am ET today Feb 17 2016
    Enzymotec misses 4Q profit forecasts Feb 17 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)